Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hypercalcemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    79 result(s) found for: Hypercalcemia. Displaying page 4 of 4.
    « Previous 1  2  3  4 
    EudraCT Number: 2019-004844-32 Sponsor Protocol Number: EMN24 Start Date*: 2020-09-09
    Sponsor Name:Stichting European Myeloma Network – EMN
    Full Title: Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologo...
    Medical condition: newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000842-36 Sponsor Protocol Number: HM12/10174 Start Date*: 2012-07-26
    Sponsor Name:University of Leeds
    Full Title: A Phase I/IIa trial of VTD-panobinostat treatment and panobinostat maintenance in relapsed and relapsed/refractory multiple myeloma patients
    Medical condition: Multiple myeloma in the relapsed and relapsed/refractory stage
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001499-20 Sponsor Protocol Number: RV-MM-GMSG-392 Start Date*: 2014-09-30
    Sponsor Name:Meletios-Athanasios Dimopoulos
    Full Title: A phase II open label, non comparative, non randomized study for the assessment of the efficacy and safety of lenalidomide + adriamycine and low dose dexamethasone combination (RAD) in newly diagno...
    Medical condition: Newly Diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004602-59 Sponsor Protocol Number: IFM2020-05-BENEFIT Start Date*: 2020-11-25
    Sponsor Name:CHU DE POITIERS
    Full Title: Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly diagnosed Non Frail transplant Ineligible Multiple Myeloma e...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002602-24 Sponsor Protocol Number: ISASOCUT Start Date*: 2023-03-31
    Sponsor Name:CHU DE POITIERS
    Full Title: Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of newly diagnosed transplant ineligible multiple myeloma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004003-46 Sponsor Protocol Number: RealMM Start Date*: 2018-09-05
    Sponsor Name:DIPARTIMENTO DI BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE-UNIVERISITÀ DI TORINO
    Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT...
    Medical condition: Newly diagnosed MM patients = 65 years old or ineligible for autologous stem cell transplant
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001990-22 Sponsor Protocol Number: 54767414LEU2002 Start Date*: 2021-08-09
    Sponsor Name:Hellenic Society of Haematology (HSH)
    Full Title: An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with...
    Medical condition: Primary plasma cell leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035223 Plasma cell leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005216-21 Sponsor Protocol Number: IFM2020-02 Start Date*: 2021-08-30
    Sponsor Name:Intergroupe Francophone du Myélome
    Full Title: MInimal residual Disease Adapted Strategy: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group...
    Medical condition: Patients with multiple myeloma, newly diagnosed and eligible for autologous stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019439-37 Sponsor Protocol Number: M10-149 Start Date*: 2010-10-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Intact Para...
    Medical condition: Moderate to Severe Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006792-42 Sponsor Protocol Number: EAE120 Start Date*: 2022-03-09
    Sponsor Name:Hellenic Society of Hematology (EAE)
    Full Title: A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Daratumumab, Lenalidomide and Dexamethasone ...
    Medical condition: newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001942-39 Sponsor Protocol Number: EAE128 Start Date*: 2022-10-24
    Sponsor Name:Hellenic Society of Hematology (EAE)
    Full Title: A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat...
    Medical condition: Newly diagnosed patients with multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015720-28 Sponsor Protocol Number: CCRG 09-003 Start Date*: 2009-12-18
    Sponsor Name:Antwerp University Hospital
    Full Title: Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma: a phase II trial.
    Medical condition: Therapeutic vaccination with dendritic cells loaded with wilms' tumor 1 protein in patients with myeloid malignancies and multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10046859 Vaccination LLT
    12.0 10024329 Leukemia LLT
    12.0 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001787-23 Sponsor Protocol Number: CSBR759A2201 Start Date*: 2008-08-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-week, open label, multicenter, titration study, with a 9-month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels i...
    Medical condition: Hyperphosphataemia in patients with Chronic Kidney Disease (CKD) on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed) GB (Completed) FI (Completed) SE (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) LT (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000184-40 Sponsor Protocol Number: 20130173 Start Date*: 2014-09-11
    Sponsor Name:Amgen, Inc.
    Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000341-19 Sponsor Protocol Number: 20050103 Start Date*: 2006-05-05
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer
    Medical condition: Metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) CZ (Completed) HU (Completed) ES (Completed) DE (Completed) NL (Completed) LT (Completed) SK (Completed) EE (Completed) SE (Completed) BE (Completed) LV (Completed) DK (Completed) IT (Completed) GR (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002381-18 Sponsor Protocol Number: VEG107769 Start Date*: 2007-03-15
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: An Open-Label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects with Renal Cell Carcinoma previously enrolled on Protocol VEG105192
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) AT (Prematurely Ended) SK (Completed) LT (Completed) EE (Completed) GR (Prematurely Ended) CZ (Completed) IT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-004618-40 Sponsor Protocol Number: 20110100 Start Date*: Information not available in EudraCT
    Sponsor Name:Amgen Inc.
    Full Title: An Open-label, Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years with Chronic Kidney Disease an...
    Medical condition: Secondary hyperparathyroidism in pediatric subjects with chronic kidney disease receiving hemodialysis or peritoneal dialysis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Temporarily Halted) PL (Completed) HU (Completed) CZ (Completed) IT (Completed) SK (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000339-93 Sponsor Protocol Number: 20050136 Start Date*: 2006-05-26
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer.
    Medical condition: Treatment of bone metastases in subjects with advanced breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) NL (Completed) SK (Completed) GB (Completed) AT (Completed) ES (Completed) DE (Completed) LT (Completed) EE (Completed) BE (Completed) SE (Completed) LV (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016138-29 Sponsor Protocol Number: APL-C-001-09 Start Date*: 2010-05-06
    Sponsor Name:Pharma Mar, S.A.
    Full Title: “Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma”.
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) ES (Completed) AT (Completed) NL (Completed) DE (Completed) BE (Completed) CZ (Completed) IT (Completed) GR (Completed) IE (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 12:27:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA